Global Irritable Bowel Syndrome Treatment Market - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025
Request Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/506
This report segments the global irritable bowel syndrome treatment market on the basis of drug type, medical condition, and distribution channel. On the basis of drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.
According to International Foundation for Functional Gastrointestinal Disorders, 2016, worldwide prevalence of irritable bowel syndrome is around 10-15%. Furthermore, there are between 2.4 and 3.5 million annual physician visits for IBS in the U.S. according to the same source. According to the Anxiety and Depression Association of America, approximately one in five adults in the U.S. is suffering with irritable bowel syndrome. Irritable bowel syndrome shows a wide range of symptoms, so, the treatment is decided on predominance of the symptoms such as, in pain predominant patients, antispasmodic agents or tricyclic antidepressants are used. The prevalence of irritable bowel syndrome is predominant in female than in males. According to the International Foundation for Functional Gastrointestinal Disorders, 2 in 3 IBS sufferers are female. Some of the U.S. Food & Drug Administration approved drugs for relieving the symptoms associated with IBS are Lotronex (Alosetron), Amitiza (Lubiprostone), Linzess (Linclotide), and Xifaxan (Rifaximin).
The number of available irritable bowel syndrome drugs has increased over the last few years and new drugs have been approved for the treatment. North America accounts for the largest share in the global irritable bowel syndrome treatment market, followed by Europe and Asia-pacific, respectively. According to an article published in the Brandon Gaille in 2017, on an average, junk food accounts for 28.8% of the total caloric intake of an American. According to Centers for Disease Control and Prevention (CDC) in 2015, it was estimated that 1.3% of U.S. adults i.e. 3 million were reported to being diagnosed with IBD. Consumption of unhealthy food in large quantities raises the bar of probability for IBS acting as a driving factor for the global market growth. Furthermore, the companies are indulged in development, distribution and marketing agreements of irritable bowel syndrome treatment drugs in selective countries such as Japan and China which is expected to drive the growth of the Asia-Pacific irritable bowel syndrome treatment market. For, instance, Sucampo Pharmaceutical, Inc. collaborated with Herbin Gloria Pharmaceuticals to commercialize its product in China in 2015.
Some major players operating in the irritable bowel syndrome treatment market are Abbott Laboratories, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., and Ironwood Pharmaceuticals, Inc.
Complete Report Details @ https://www.coherentmarketinsights.com/press-release/irritable-bowel-syndrome-treatment-market-to-surpass-us-2300-million-threshold-by-2025-globally-with-north-america-positioned-as-the-growth-engine-240
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Irritable Bowel Syndrome Treatment Market - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025 here
News-ID: 952999 • Views: 434
More Releases from CMI - Pharmaceutical Research
Global Pulmonary Arterial Hypertension (PAH) Market - Pfizer, Inc., Actelion Pha …
Pulmonary hypertension or PH is a condition in which the blood pressure rises in the pulmonary artery, vein, or capillaries (collectively known as lung vasculature), which might lead to shortness of breath, fainting, leg swelling, and dizziness, among others. Pulmonary hypertension may be a relentless disease with a noticeable reduction in exercise tolerance. Pulmonary arterial hypertension or PAH indicates that the patient has high blood pressure in arteries that carry
Betaxolol Market - Size, Share, Growth, Outlook, and Trends Analysis 2018–2026
Betaxolol is a racemic mixture and beta-adrenergic receptor inhibitor used to treat patients with chronic open-angle glaucoma or ocular hypertension. It was first approved by the U.S. Food and Drug Administration (FDA) in 1989, as an oral tablet. Betaxolol is used either alone or in combination with other medicines to lower down the pressure within the heart or eye. In the heart, Betaxolol decreases the cardiac contractility and rate selectively
Gene Therapy Market - Size, Share, Outlook, and Opportunity Analysis, 2018-2026
Genes are composed of deoxyribonucleic acid (DNA), which contains essential information for producing proteins that are crucial for the optimal functioning of the body. Genetic disorder is the result of gene mutations in which proteins are made incorrectly. Gene therapy is intended to introduce healthy gene into damaged cells to counteract for abnormal genes or to make a protein of interest. Mutated gene causes missing of the important protein, with
Cervical Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2 …
Cervical cancer develops in women’s cervix, and mainly affects sexually active women aged between 30 and 45. Cervical cancer often shows no symptoms in early stages. However, the death rate of cervical cancer can be significantly reduced with use of Pap test (Papanicolaou test): a screening procedure which can detect the changes in the cervix before the cancer develops. There are different types of cervical cancer, out of which two
More Releases for IBS
Integrated Bridge Systems Market Report 2018: Segmentation by Platform (Commerci …
Global Integrated Bridge Systems market research report provides company profile for Northrop Grumman Sperry Marine (U.K.), Raytheon Anschütz (Germany), Rolls Royce (U.K.), L-3 Communications Mapps Inc. (Canada), FURUNO Electric Shokai Ltd. (Japan) and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR
IBS' solution to power China’s first Cruise Line
Trivandrum, 16 January 2013: Henna, the largest cruise ship in mainland China will run on IBS’ inventory and pricing management solution, Cruise Partner, when it makes its maiden journey on January 26, 2013. China based HNA Tourism Cruise and Yacht Management Company unveiled this cruise ship on November 28, 2012. Henna has 739 rooms for 1,965 passengers, as well as a complete range of facilities for living and entertainment. HNA
Vikash Sureka joins IBS as Chief Financial Officer
Trivandrum (India), 17 May 2012: IBS Software Services, the leading provider of new-generation IT solutions to the global aviation industry, has appointed Mr Vikash Sureka as its Chief Financial Officer. He will head the Finance, Legal, Company Affairs and Administration functions of IBS operations world-wide. A Chartered Accountant, Vikash has over 19 years of experience mostly in senior executive roles managing business globally with proven proficiency in Investor Relations, P&L
HaCon and IBS combine expertise in railway operation
Hanover (2010-07-06). Two Hanoverian companies now combine their expertise in questions of railway operations: With effect from 1 July 2010, the HaCon Ingenieurgesellschaft mbH, took over the engineering firm for railway operating systems (Ingenieurbüro für Bahnbetriebssysteme GmbH – IBS). This way HaCon expanded its services to include the areas operation simulation, vehicle and personnel planning and construction operations planning. This also includes consulting services concerning railway systems issues, such as travel
Raytheon Anschütz IBS for new Intership Bulkers
Raytheon Anschütz was recently awarded a contract to supply their Integrated Bridge System (IBS) to two new bulk carriers. The bulkers will be built at New Times Shipyard in Jingjiang, China. The delivery to the Cyprus based shipping company Intership Navigation Co. Ltd., a member of the German Hartmann Group, is scheduled for August and October 2011. The new bulkers, each with a capacity of 176,000 dwt, will be equipped
CoCoNet enhances MULTIVERSA IBS by OFTP access protocol
CoCoNet enhances the modern e-banking-platform MULTIVERSA IBS International Banking Server through an OFTP access channel (Odette File Transfer Protocol) for the data transmission between international banks and corporate customers. MULTIVERSA IBS is a modular and scalable platform for receiving and processing payment transaction data and delivering customer specific account information like account statements, intraday reports, returns and foreign exchange rate information. The initial situation at banks that now also offer